CoChat

Anticancer Therapeutic Strategies Targeting p53 Aggregation

Ferretti, Giulia D. S., Quarti, Julia, dos Santos, Gileno, Rangel, Luciana P., Silva, Jerson L. · 2022 · International Journal of Molecular Sciences
Cited by 24

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include chemoresistance, which makes therapy even more difficult. The therapies available for the treatment of cancer are still quite limited, so the study of new molecules and therapeutic targets focusing on p53 aggregates is a promising strategy against cancer. In this review, we classify anticancer molecules with antiaggregation properties into four categories: thiol alkylating agents, designed peptides, agents with chaperone-based mechanisms that inhibit p53 aggregation, and miscellaneous compounds with anti-protein aggregation properties that have been studied in neurodegenerative diseases. Furthermore, we highlight autophagy as a possible degradation pathway for aggregated p53. Here, considering cancer as a protein aggregation disease, we review strategies that have been used to disrupt p53 aggregates, leading to cancer regression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms231911023

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 131

  1. Kern, 1992, Definition of a Consensus Binding Site for P53, Nat. Genet., 1, 45, 10.1038/ng0492-45 · DOI · Paper page
  2. Lane, 1992, P53, Guardian of the Genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  3. Hupp, 1999, Regulation of P53 Protein Function through Alterations in Protein-Folding Pathways, Cell. Mol. Life Sci., 55, 88, 10.1007/s000180050272 · DOI
  4. Bullock, 2000, Quantitative Analysis of Residual Folding and DNA Binding in Mutant P53 Core Domain: Definition of Mutant States for Rescue in Cancer Therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  5. Joerger, 2006, Structural Basis for Understanding Oncogenic P53 Mutations and Designing Rescue Drugs, Proc. Natl. Acad. Sci. USA, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  6. Flores, 2002, Targeted Point Mutations of P53 Lead to Dominant-Negative Inhibition of Wild-Type P53 Function, Proc. Natl. Acad. Sci. USA, 99, 2948, 10.1073/pnas.052713099 · DOI · Paper page
  7. Prives, 2012, Mutant P53: One Name, Many Proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
  8. 2021, Mutant P53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches, Front. Cell Dev. Biol., 8, 607670, 10.3389/fcell.2020.607670 · DOI · Paper page
  9. Stein, Y., Rotter, V., and Aloni-Grinstein, R. (2019). Gain-of-Function Mutant P53: All the Roads Lead to Tumorigenesis. Int. J. Mol. Sci., 20. · DOI · Paper page
  10. Ishimaru, 2003, Fibrillar Aggregates of the Tumor Suppressor P53 Core Domain, Biochemistry, 42, 9022, 10.1021/bi034218k · DOI · Paper page
  11. Rotter, 1983, P53, a Transformation-Related Cellular-Encoded Protein, Can Be Used As a Biochemical Marker for the Detection of Primary Mouse Tumor Cells, Proc. Natl. Acad. Sci. USA, 80, 2613, 10.1073/pnas.80.9.2613 · DOI · Paper page
  12. Moll, 1992, Two Distinct Mechanisms Alter P53 in Breast Cancer: Mutation and Nuclear Exclusion, Proc. Natl. Acad. Sci. USA, 89, 7262, 10.1073/pnas.89.15.7262 · DOI · Paper page
  13. Bullock, 1997, Thermodynamic Stability of Wild-Type and Mutant P53 Core Domain, Proc. Natl. Acad. Sci. USA, 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
  14. Rangel, 2012, Mutant P53 Aggregates into Prion-like Amyloid Oligomers and Fibrils: Implications for Cancer, J. Biol. Chem., 287, 28152, 10.1074/jbc.M112.340638 · DOI · Paper page
  15. Clos, 2013, Dual Role of P53 Amyloid Formation in Cancer; Loss of Function and Gain of Toxicity, Biochem. Biophys. Res. Commun., 430, 963, 10.1016/j.bbrc.2012.11.130 · DOI
  16. Gogna, 2012, Chaperoning of Mutant P53 Protein by Wild-Type P53 Protein Causes Hypoxic Tumor Regression, J. Biol. Chem., 287, 2907, 10.1074/jbc.M111.317354 · DOI
  17. Levy, 2011, Co-Localization of Mutant P53 and Amyloid-like Protein Aggregates in Breast Tumors, Int. J. Biochem. Cell Biol., 43, 60, 10.1016/j.biocel.2010.10.017 · DOI · Paper page
  18. Xu, 2011, Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  19. Rangel, 2014, The Aggregation of Mutant P53 Produces Prion-like Properties in Cancer, Prion, 8, 75, 10.4161/pri.27776 · DOI · Paper page
  20. Silva, 2014, Prion-like Aggregation of Mutant P53 in Cancer, Trends Biochem. Sci., 39, 260, 10.1016/j.tibs.2014.04.001 · DOI · Paper page
  21. Hompes, 2017, Nuclear Inclusion Bodies of Mutant and Wild-Type P53 in Cancer: A Hallmark of P53 Inactivation and Proteostasis Remodelling by P53 Aggregation, J. Pathol., 242, 24, 10.1002/path.4872 · DOI · Paper page
  22. Petronilho, 2021, Phase Separation of P53 Precedes Aggregation and Is Affected by Oncogenic Mutations and Ligands, Chem. Sci., 12, 7334, 10.1039/D1SC01739J · DOI · Paper page
  23. Yang, 2021, Mesoscopic Protein-Rich Clusters Host the Nucleation of Mutant P53 Amyloid Fibrils, Proc. Natl. Acad. Sci. USA, 118, e2015618118, 10.1073/pnas.2015618118 · DOI · Paper page
  24. Wawrzynow, 2018, Chaperoning the Guardian of the Genome. The Two-Faced Role of Molecular Chaperones in P53 Tumor Suppressor Action, Biochim. Biophys. Acta—Rev. Cancer, 1869, 161, 10.1016/j.bbcan.2017.12.004 · DOI
  25. Rangel, 2015, Misfolding, Aggregation, and Disordered Segments in c-Abl and P53 in Human Cancer, Front. Oncol., 5, 97
  26. Pedrote, 2020, Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant P53 Amyloid Oligomers, iScience, 23, 100820, 10.1016/j.isci.2020.100820 · DOI · Paper page
  27. Forget, K.J., Tremblay, G., and Roucou, X. (2013). P53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular P53. PLoS ONE, 8. · DOI · Paper page
  28. Rangel, 2019, P53 Reactivation with Induction of Massive Apoptosis-1 (PRIMA-1) Inhibits Amyloid Aggregation of Mutant P53 in Cancer Cells, J. Biol. Chem., 294, 3670, 10.1074/jbc.RA118.004671 · DOI · Paper page
  29. Baudino, 2015, Targeted Cancer Therapy: The Next Generation of Cancer Treatment, Curr. Drug Discov. Technol., 12, 3, 10.2174/1570163812666150602144310 · DOI · Paper page
  30. Liu, 2019, The Past, Present and Future of Potential Small-Molecule Drugs Targeting P53-MDM2/MDMX for Cancer Therapy, Eur. J. Med. Chem., 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI · Paper page
  31. Parrales, 2015, Targeting Oncogenic Mutant P53 for Cancer Therapy, Front. Oncol., 5, 288, 10.3389/fonc.2015.00288 · DOI · Paper page
  32. Gomes, A.S., Ramos, H., and Inga, A. (2021). Structural and Drug Targeting Insights on Mutant P53. Cancers, 13. · DOI · Paper page
  33. Mizuno, 2010, Mutant P53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway, Cell, 148, 244
  34. Lamark, 2012, Aggrephagy: Selective Disposal of Protein Aggregates by Macroautophagy, Int. J. Cell Biol., 2012, 736905, 10.1155/2012/736905 · DOI · Paper page
  35. Soteras, 2015, P53 Protein Aggregation Promotes Platinum Resistance in Ovarian Cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
  36. Jung, 2020, Autophagy as a Decisive Process for Cell Death, Exp. Mol. Med., 52, 921, 10.1038/s12276-020-0455-4 · DOI · Paper page
  37. Xu, 2021, Regulation of P53 Stability as a Therapeutic Strategy for Cancer, Biochem. Pharmacol., 185, 114407, 10.1016/j.bcp.2021.114407 · DOI
  38. Chin, 1992, Modulation of Activity of the Promoter of the Human MDR1 Gene by Ras and P53, Science, 255, 459, 10.1126/science.1346476 · DOI · Paper page
  39. Zastawny, 1993, The Core Promoter Region of the P-Glycoprotein Gene Is Sufficient to Confer Differential Responsiveness to Wild-Type and Mutant P53, Oncogene, 8, 1529
  40. Chan, 2004, Mutant P53 Expression Enhances Drug Resistance in a Hepatocellular Carcinoma Cell Line, Cancer Chemother. Pharmacol., 53, 519, 10.1007/s00280-004-0767-4 · DOI · Paper page
  41. Blandino, 1999, Mutant P53 Gain of Function: Differential Effects of Different P53 Mutants on Resistance of Cultured Cells to Chemotherapy, Oncogene, 18, 477, 10.1038/sj.onc.1202314 · DOI · Paper page
  42. Tsang, 2005, P53-R175H Mutant Gains New Function in Regulation of Doxorubicin-Induced Apoptosis, Int. J. Cancer, 114, 331, 10.1002/ijc.20818 · DOI · Paper page
  43. Chee, 2013, Wild-Type and Mutant P53 Mediate Cisplatin Resistance through Interaction and Inhibition of Active Caspase-9, Cell Cycle, 12, 278, 10.4161/cc.23054 · DOI · Paper page
  44. Do, 2012, Mutant P53 Cooperates with ETS2 to Promote Etoposide Resistance, Genes Dev., 26, 830, 10.1101/gad.181685.111 · DOI · Paper page
  45. Xu, 2014, Unequal Prognostic Potentials of P53 Gain-of-Function Mutations in Human Cancers Associate with Drugmetabolizing Activity, Cell Death Dis., 5, e1108, 10.1038/cddis.2014.75 · DOI · Paper page
  46. Zhang, 2017, Proteomic Identification of ERP29 as a Key Chemoresistant Factor Activated by the Aggregating P53 Mutant ARG282TRP, Oncogene, 36, 5473, 10.1038/onc.2017.152 · DOI
  47. Wang, 2013, Mutant TP53 Enhances the Resistance of Glioblastoma Cells to Temozolomide by Up-Regulating O6-Methylguanine DNA-Methyltransferase, Neurol. Sci., 34, 1421, 10.1007/s10072-012-1257-9 · DOI
  48. Lee, 2010, Implication of Necrosis-Linked P53 Aggregation in Acquired Apoptotic Resistance to 5-FU in MCF-7 Multicellular Tumour Spheroids, Oncol. Rep., 24, 73
  49. Singh, 2021, Mechanisms of Temozolomide Resistance in Glioblastoma—A Comprehensive Review, Cancer Drug Resist., 4, 17
  50. Hu, 2021, Targeting Mutant P53 for Cancer Therapy: Direct and Indirect Strategies, J. Hematol. Oncol., 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
  51. Wang, 2017, Multisite Aggregation of P53 and Implications for Drug Rescue, Proc. Natl. Acad. Sci. USA, 114, E2634
  52. Kanapathipillai, M. (2018). Treating P53 Mutant Aggregation-Associated Cancer. Cancers, 10. · DOI · Paper page
  53. Bauer, 2016, 2-Sulfonylpyrimidines: Mild Alkylating Agents with Anticancer Activity toward P53-Compromised Cells, Proc. Natl. Acad. Sci. USA, 113, E5271, 10.1073/pnas.1610421113 · DOI · Paper page
  54. Palanikumar, 2021, Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function, Nat. Commun., 12, 3962, 10.1038/s41467-021-23985-1 · DOI · Paper page
  55. Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., and Memarzadeh, S. (2021). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers, 13. · DOI · Paper page
  56. Zhang, 2020, Therapeutic Potential of ReACp53 Targeting Mutant P53 Protein in CRPC, Prostate Cancer Prostatic Dis., 23, 160, 10.1038/s41391-019-0172-z · DOI · Paper page
  57. Miller, 2019, Bifunctional Ligand Design for Modulating Mutant P53 Aggregation in Cancer, Chem. Sci., 10, 10802, 10.1039/C9SC04151F · DOI · Paper page
  58. Bauer, 2019, A Structure-Guided Molecular Chaperone Approach for Restoring the Transcriptional Activity of the P53 Cancer Mutant Y220C, Future Med. Chem., 11, 2491, 10.4155/fmc-2019-0181 · DOI · Paper page
  59. Chen, 2017, Inhibition of P53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride, Protein Pept. Lett., 24, 353, 10.2174/0929866524666170123142858 · doi:10.2174/0929866524666170123142858
  60. Campos, 2018, Resveratrol Prevents P53 Aggregation in Vitro and in Breast Cancer Cells, Oncotarget, 9, 29112, 10.18632/oncotarget.25631 · DOI · Paper page
  61. Chen, 2017, Polyarginine and Its Analogues Inhibit P53 Mutant Aggregation and Cancer Cell Proliferation in Vitro, Biochem. Biophys. Res. Commun., 489, 130, 10.1016/j.bbrc.2017.05.111 · DOI
  62. Zhang, 2018, Role of Thiol Reactivity for Targeting Mutant P53, Cell Chem. Biol., 25, 1219, 10.1016/j.chembiol.2018.06.013 · DOI · Paper page
  63. Butturini, E., Butera, G., Pacchiana, R., de Prati, A.C., Mariotto, S., and Donadelli, M. (2021). Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant P53 Isoforms. Cells, 10. · DOI
  64. Kaar, 2010, Stabilization of Mutant P53 via Alkylation of Cysteines and Effects on DNA Binding, Protein Sci., 19, 2267, 10.1002/pro.507 · DOI · Paper page
  65. Hainaut, 1993, Redox Modulation of P53 Conformation and Sequence-Specific DNA Binding in Vitrol, Cancer Res., 53, 4469
  66. Sun, 2003, Formation of Disulfide Bond in P53 Correlates with Inhibition of DNA Binding and Tetramerization, Antioxid. Redox Signal., 5, 655, 10.1089/152308603770310338 · DOI · Paper page
  67. Bykov, 2002, Mutant P53-Dependent Growth Suppression Distinguishes PRIMA-1 from Known Anticancer Drugs: A Statistical Analysis of Information in the National Cancer Institute Database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
  68. Li, 2015, PRIMA-1met (APR-246) Inhibits Growth of Colorectal Cancer Cells with Different P53 Status through Distinct Mechanisms, Oncotarget, 6, 36689, 10.18632/oncotarget.5385 · DOI · Paper page
  69. Krayem, 2016, P53 Reactivation by PRIMA-1Met (APR-246) Sensitises V600E/KBRAF Melanoma to Vemurafenib, Eur. J. Cancer, 55, 98, 10.1016/j.ejca.2015.12.002 · DOI
  70. Piyawajanusorn, 2019, PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells, Cancer Genom. Proteom., 16, 543, 10.21873/cgp.20156 · DOI
  71. Bykov, 2005, Reactivation of Mutant P53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs, J. Biol. Chem., 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  72. Liang, 2007, Re-Activation of the P53 Pathway Inhibits in Vivo and in Vitro Growth of Hormone-Dependent Human Breast Cancer Cells, Int. J. Oncol., 31, 777
  73. Zache, 2008, PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant P53, Cell. Oncol., 30, 411
  74. Shi, 2008, In Vitro and in Vivo Cytotoxic Effects of PRIMA-1 on Hepatocellular Carcinoma Cells Expressing Mutant P53ser249, Carcinogenesis, 29, 1428, 10.1093/carcin/bgm266 · DOI · Paper page
  75. Zandi, 2011, PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant P53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
  76. Spicer, 2014, Selective Chemical Protein Modification, Nat. Commun., 5, 4740, 10.1038/ncomms5740 · DOI · Paper page
  77. Wassman, 2013, Computational Identification of a Transiently Open L1/S3 Pocket for Reactivation of Mutant P53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
  78. Cino, 2016, Aggregation Tendencies in the P53 Family Are Modulated by Backbone Hydrogen Bonds, Sci. Rep., 6, 32535, 10.1038/srep32535 · DOI · Paper page
  79. Ghosh, 2014, Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in P53, Biochemistry, 53, 5995, 10.1021/bi500825d · DOI · Paper page
  80. Goldschmidt, 2010, Identifying the Amylome, Proteins Capable of Forming Amyloid-like Fibrils, Proc. Natl. Acad. Sci. USA, 107, 3487, 10.1073/pnas.0915166107 · DOI · Paper page
  81. Blagosklonny, 2001, Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death, JNCI J. Natl. Cancer Inst., 93, 239, 10.1093/jnci/93.3.239-a · doi:10.1093/jnci/93.3.239-a
  82. Saibil, 2013, Chaperone Machines for Protein Folding, Unfolding and Disaggregation, Nat. Rev. Mol. Cell Biol., 14, 630, 10.1038/nrm3658 · DOI · Paper page
  83. Blanden, 2020, Zinc Shapes the Folding Landscape of P53 and Establishes a Pathway for Reactivating Structurally Diverse Cancer Mutants, eLife, 9, e61487, 10.7554/eLife.61487 · DOI · Paper page
  84. Rosenzweig, 2002, Metallochaperones: Bind and Deliver, Chem. Biol., 9, 673, 10.1016/S1074-5521(02)00156-4 · DOI · Paper page
  85. Givol, 2012, P53 Reactivation The Link to Zinc, Cell Cycle, 11, 2581, 10.4161/cc.21020 · DOI
  86. Formigari, 2013, The Effect of Zinc and the Role of P53 in Copper-Induced Cellular Stress Responses, J. Appl. Toxicol., 33, 527, 10.1002/jat.2854 · DOI
  87. Butler, 2003, Structure, Function, and Aggregation of the Zinc-Free Form of the P53 DNA Binding Domain, Biochemistry, 42, 2396, 10.1021/bi026635n · DOI · Paper page
  88. Richard, 2000, Metalloregulation of the Tumor Suppressor Protein P53: Zinc Mediates the Renaturation of P53 after Exposure to Metal Chelators in Vitro and in Intact Cells, Oncogene, 19, 5227, 10.1038/sj.onc.1203907 · DOI · Paper page
  89. Yu, 2014, Small Molecule Restoration of Wildtype Structure and Function of Mutant P53 Using a Novel Zinc-Metallochaperone Based Mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
  90. Wang, 2012, First-Order Rate-Determining Aggregation Mechanism of P53 and Its Implications, Proc. Natl. Acad. Sci. USA, 109, 13590, 10.1073/pnas.1211557109 · DOI · Paper page
  91. Blanden, 2015, Erratum: Synthetic Metallochaperone ZMC1 Rescues Mutant P53 Conformation by Transporting Zinc into Cells as an Ionophore, Mol. Pharmacol., 88, 1084, 10.1124/mol.115.097550err · doi:10.1124/mol.115.097550err
  92. Garufi, 2013, A Fluorescent Curcumin-Based Zn(II)-Complex Reactivates Mutant (R175H and R273H) P53 in Cancer Cells, J. Exp. Clin. Cancer Res., 32, 72, 10.1186/1756-9966-32-72 · DOI · Paper page
  93. Hartl, 2011, Molecular Chaperones in Protein Folding and Proteostasis, Nature, 475, 324, 10.1038/nature10317 · DOI · Paper page
  94. Doyle, 2013, Protein Rescue from Aggregates by Powerful Molecular Chaperone Machines, Nat. Rev. Mol. Cell Biol., 14, 617, 10.1038/nrm3660 · DOI · Paper page
  95. Yu, 2012, Allele-Specific P53 Mutant Reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  96. Boeckler, 2008, Targeted Rescue of a Destabilized Mutant of P53 by Ar in Silico Screened Drug, Chemtracts, 21, 236
  97. Basse, 2010, Toward the Rational Design of P53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant, Chem. Biol., 17, 46, 10.1016/j.chembiol.2009.12.011 · DOI · Paper page
  98. Wilcken, 2012, Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant P53, J. Am. Chem. Soc., 134, 6810, 10.1021/ja301056a · DOI · Paper page
  99. Joerger, 2015, Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant P53, Structure, 23, 2246, 10.1016/j.str.2015.10.016 · DOI · Paper page
  100. Bauer, 2016, Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of P53 Mutant Y220C Rescue Drugs, ACS Chem. Biol., 11, 2265, 10.1021/acschembio.6b00315 · DOI · Paper page
  101. Baud, 2018, Aminobenzothiazole Derivatives Stabilize the Thermolabile P53 Cancer Mutant Y220C and Show Anticancer Activity in P53-Y220C Cell Lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI · Paper page
  102. Huang, 2021, DAXX Represents a New Type of Protein-Folding Enabler, Nature, 597, 132, 10.1038/s41586-021-03824-5 · DOI · Paper page
  103. Ross, 2004, Protein Aggregation and Neurodegenerative Disease, Nat. Med., 10, S10, 10.1038/nm1066 · DOI · Paper page
  104. Goedert, 2015, Alzheimer’s and Parkinson’s Diseases: The Prion Concept in Relation to Assembled Aβ, Tau, and α-Synuclein, Science, 349, 61, 10.1126/science.1255555 · DOI · Paper page
  105. Bredesen, 2006, Cell Death in the Nervous System, Nature, 443, 796, 10.1038/nature05293 · DOI · Paper page
  106. Klabunde, 2000, Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors, Nat. Struct. Biol., 7, 312, 10.1038/74082 · DOI
  107. Evers, 2009, Elucidating the Mechanism of Lipid Membrane-Induced IAPP Fibrillogenesis and Its Inhibition by the Red Wine Compound Resveratrol: A Synchrotron X-ray Reflectivity Study, J. Am. Chem. Soc., 131, 9516, 10.1021/ja8097417 · DOI · Paper page
  108. Feng, 2009, Resveratrol Inhibits Beta-Amyloid Oligomeric Cytotoxicity but Does Not Prevent Oligomer Formation, Neurotoxicology, 30, 986, 10.1016/j.neuro.2009.08.013 · DOI · Paper page
  109. Florio, 2015, Transthyretin Binding Heterogeneity and Antiamyloidogenic Activity of Natural Polyphenols and Their Metabolites, J. Biol. Chem., 290, 29769, 10.1074/jbc.M115.690172 · DOI
  110. Gautam, 2017, Polyphenols in Combination with β-Cyclodextrin Can Inhibit and Disaggregate α-Synuclein Amyloids under Cell Mimicking Conditions: A Promising Therapeutic Alternative, Biochim. Biophys. Acta—Proteins Proteom., 1865, 589, 10.1016/j.bbapap.2017.02.014 · DOI
  111. Kulikov, 2015, Amphiphilic Oligoamide α-Helix Peptidomimetics Inhibit Islet Amyloid Polypeptide Aggregation, Tetrahedron Lett., 56, 3670, 10.1016/j.tetlet.2015.02.132 · DOI
  112. Kumar, 2015, Islet Amyloid-Induced Cell Death and Bilayer Integrity Loss Share a Molecular Origin Targetable with Oligopyridylamide-Based α-Helical Mimetics, Chem. Biol., 22, 369, 10.1016/j.chembiol.2015.01.006 · DOI · Paper page
  113. Kumar, 2017, α-Helix Mimetics as Modulators of Aβ Self-Assembly, J. Am. Chem. Soc., 139, 5744, 10.1021/jacs.6b09734 · DOI · Paper page
  114. Kumar, 2018, Peptidomimetic-Based Multidomain Targeting Offers Critical Evaluation of Aβ Structure and Toxic Function, J. Am. Chem. Soc., 140, 6562, 10.1021/jacs.7b13401 · DOI · Paper page
  115. Hyun, S., and Shin, D. (2021). Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases. Life, 11. · DOI · Paper page
  116. Alexandrova, 2015, Improving Survival by Exploiting Tumour Dependence on Stabilized Mutant P53 for Treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
  117. Masciarelli, 2014, Gain-of-Function Mutant P53 Downregulates MiR-223 Contributing to Chemoresistance of Cultured Tumor Cells, Oncogene, 33, 1601, 10.1038/onc.2013.106 · DOI · Paper page
  118. Shi, 2021, Mutant P53 as a Regulator and Target of Autophagy, Front. Oncol., 10, 607149, 10.3389/fonc.2020.607149 · DOI
  119. Thorburn, 2020, Autophagy in Cancer: Moving from Understanding Mechanism to Improving Therapy Responses in Patients, Cell Death Differ., 27, 843, 10.1038/s41418-019-0474-7 · DOI · Paper page
  120. Mizushima, 2020, Autophagy Assays for Biological Discovery and Therapeutic Development, Trends Biochem. Sci., 45, 1080, 10.1016/j.tibs.2020.07.006 · DOI · Paper page
  121. Xu, 2020, Molecular Regulation of Autophagy Machinery by MTOR-Dependent and -Independent Pathways, Ann. N. Y. Acad. Sci., 1467, 3, 10.1111/nyas.14305 · DOI · Paper page
  122. Luo, 2018, HMGB1 Represses the Anti-Cancer Activity of Sunitinib by Governing TP53 Autophagic Degradation via Its Nucleus-to-Cytoplasm Transport, Autophagy, 14, 2155, 10.1080/15548627.2018.1501134 · DOI
  123. Rodriguez, 2012, Dietary Downregulation of Mutant P53 Levels via Glucose Restriction: Mechanisms and Implications for Tumor Therapy, Cell Cycle, 11, 4436, 10.4161/cc.22778 · DOI · Paper page
  124. Yao, 2010, The Role of Ubiquitin in Autophagy-Dependent Protein Aggregate Processing, Genes Cancer, 1, 779, 10.1177/1947601910383277 · DOI · Paper page
  125. Pankiv, 2007, P62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy, J. Biol. Chem., 282, 24131, 10.1074/jbc.M702824200 · DOI · Paper page
  126. Gubas, 2022, A Guide to the Regulation of Selective Autophagy Receptors, FEBS J., 289, 75, 10.1111/febs.15824 · DOI · Paper page
  127. Ma, 2022, CCT2 Is an Aggrephagy Receptor for Clearance of Solid Protein Aggregates, Cell, 185, 1325, 10.1016/j.cell.2022.03.005 · DOI · Paper page
  128. Biel, 2020, Mitochondrial Dysfunction Generates Aggregates That Resist Lysosomal Degradation in Human Breast Cancer Cells, Cell Death Dis., 11, 460, 10.1038/s41419-020-2658-y · DOI
  129. Maan, 2018, CHIP Promotes Autophagy-Mediated Degradation of Aggregating Mutant P53 in Hypoxic Conditions, FEBS J., 285, 3197, 10.1111/febs.14602 · DOI · Paper page
  130. Haque, 2018, Blocking Mutation Independent P53 Aggregation by Emodin Modulates Autophagic Cell Death Pathway in Lung Cancer, Int. J. Biochem. Cell Biol., 96, 90, 10.1016/j.biocel.2018.01.014 · DOI
  131. Choudhury, 2013, Dissecting the Pathways That Destabilize Mutant P53: The Proteasome or Autophagy?, Cell Cycle, 12, 1022, 10.4161/cc.24128 · DOI · Paper page

Cited by

See all 24

Metadata

Authors
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-09-20
Volume
23
Issue
19
Pages
11023
ISSN
1422-0067
Cited by
24
References
23
Language
en
Funders
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.